Hospital-acquired pneumonia medical therapy
Hospital-acquired pneumonia Microchapters
Differentiating Hospital-Acquired Pneumonia from other Diseases
Hospital-acquired pneumonia medical therapy On the Web
American Roentgen Ray Society Images of Hospital-acquired pneumonia medical therapy
Directions to Hospitals Treating Hospital-acquired pneumonia
Risk calculators and risk factors for Hospital-acquired pneumonia medical therapy
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. ; Philip Marcus, M.D., M.P.H.Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S ; Alejandro Lemor, M.D. 
Antimicrobial therapy is indicated in hospital-acquired penumonia. The medical regimen in patients with hospital-acquired pneumonia depends on the risk factors and the likelihood of drug resistance pathogens. For patients with no risk factors for multidrug-resistant pathogens, the regimen consists of one antibiotic, usually Ceftriaxone or a Fluoroquinolone. For patients with risk of multidrug-resistant pathogens, a three drug combination regimen is preferred.
American Thoracic Society and Infectious Diseases Society of America Guidelines from 2017: The most recent clinical practice guidelines from the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) are from 2016, and replace the 2005 IDSA clinical practice guidelines the treatment regimen will depend on the risk factors and the likelihood of drug resistance
- The duration of the antimicrobial therapy should be individualize based on the patient clinical response. The usual duration is 7 days, but the causative pathogen can change the duration of this.
- Choosing antibiotic regimens that are concordant with the American Thoracic Society and Infectious Diseases Society of America Guidelines published in 2005 may not improve outcomes.
- Antibiotic instead should be chosen based on risk of multidrug-resistant pathogens
- "Prior intravenous antibiotic use within 90 days"
- "hospitalization in a unit where >20% of S. aureus isolates are methicillin resistant, or the prevalence of MRSA is not known"
- Increased risk of mortality due to either requiring ventilatory support due to hospital-acquired pneumonia or presence of septic shock
American Thoracic Society and Infectious Diseases Society of America Guidelines from 2005:
- Health care-associated pneumonia
- 1 Empiric antimicrobial therapy
- 1.1 No risk factors for multi drug resistance
- Preferred Regimen : Ceftriaxone 1-2 g q24h IV or IM (max: 4 g/day) OR Levofloxacin 750 mg q24h for 7-14 days OR Moxifloxacin 400 mg PO/IV q24h for 7-14 days OR Ciprofloxacin 400 mg PO q8h for 10-14 days OR Ampicillin sulbactam 1-2 g q6-8h IV/IM (maximum: 8 g/day) OR Ertapenem 1 g IM/IV q24h for 10-14 days.
- 1.2 Risk factors for multi drug resistance
- Preferred Regimen: (Cefepime 1-2 g q8-12h OR Ceftazidime 2 g q8h OR Imipenem 500 mg q6h or 1g q8h OR Meropenem 1 g q8h OR Piperacillin-tazobactam 4.5 g q6h) AND (Ciprofloxacin 400 mg q8h OR Levofloxacin 750 mg q24h OR Amikacin 20 mg/kg per day OR Gentamycin 7 mg/kg per day OR Tobramycin 7 mg/kg per day) AND (Linezolid 600 mg q12h OR Vancomycin 15 mg/kg q12h).
- Note (1): Health care-associated pneumonia used to designate large diverse population of patients with many co-morbidities who reside in nursing homes, other long-term care facilities, require home intravenous therapy (or) are dialysis patients. Pneumonia in these patients frequently resembles hospital-acquired pneumonia.
- Note (2): Trough levels for Gentamycin and Tobramycin should be less than 1 g/ml, and for Amikacin they should be less than 4-5 g/ml.
- Note (3): Trough levels for Vancomycin should be 15-20 g/ml.
Methicillin-Resistant Staphylococcus Aureus
High Risk Patients
- Critically ill patients
- History of recent antibiotic therapy
- Patient admitted in a hospital with increased incidence of MRSA.
Antibiotic Choice for MRSA
- Vancomycin (15-20 mg/kg q8hr or q12 hr in patients with normal renal function and target vancomycin of 15 - 20 mg/L)
- Linezolid - 600 mg twice daily IV or orally
- Clindamycin if documented susceptibility present
- In case no MRSA is isolated on culture these antibiotics should be discontinued.
Advantages of Linezolid over Vancomycin
Methicillin-resistant staphylococcus aureus is a common isolate in the patients with Hospital-acquired pneumonia. The treatment options commonly used are vancomycin, linezolid, and clindamycin. Linezolid may be preferred in patients with renal insufficiency as the nephrotoxicity with linezolid is less compared to vancomycin. Additionally, in patients with vancomycin MIC ≥ 2mcg/mL linezolid is preferred. Linezolid resistance and failure are rare.
Side-effects of Linezolid
- Gastrointestinal side-effects
- Renal dysfunction
Side-effects of Vancomycin
- Renal toxicity were more common in vancomycin compared to linezolid
Supportive Trial Data 
In a study done in 1184 patients treated with linezolid and vancomycin no significant difference in 60 days mortality were found between the two groups. The side-effects profile were similar in both the groups however nephrotoxicity was commoner in the vancomycin group. Linezolid was found to be non-inferior to vancomycin for clinical outcome, and microbiologic outcome at end of treatment and end of study.
Methicillin Sensitive Staphylococcus Aureus
- If the culture grows methicillin sensitive staphylococcus aureus then empiric treatment for MRSA should be stopped and MSSA agents such as nafcillin (2g iv Q4hrly) or oxacillin (2g iv Q4hrly) should be started.
Gram Negative Pathogen
- There is a lack of consensus regarding the choice of antibiotics for gram negative pathogens in ventilator associated pneumonia, and health care associated pneumonia.
- Large randomized clinical trials regarding the choice of anti-microbial agents in these conditions are lacking.
- Many hospitals prefer combination drug therapy over monotherpy in these conditions. The rationale behind these are:
- Wide coverage of pathogenic strains
- Avoidance of development of antibiotic resistant strains.
- In ICU settings cephalosporins should be avoided as monotherapy, due to problems of developments of resistant organism.
- The preferred agants in ICU settings are: carbapenem (ertapenem, meropenem, doripenem, and imipenem-cilastatin).
At Risk Population
- Diabetes mellitus
- Chronic renal insufficiency
- Pulmonary diseases
- Hospitals with water supplies infected with legionella
- A beta-lactam-beta-lactamase inhibitor combination
Major Points and Recommendations for Initial Antibiotic Therapy in Adults with Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia 
Major Points and Recommendations for Initial Antibiotic Therapy
For Level of evidence and classes click here.
Major Points and Recommendations for Selected MDR Pathogens
For Level of evidence and classes click here.
- ↑ Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB; et al. (2016). "Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society". Clin Infect Dis. 63 (5): e61–e111. doi:10.1093/cid/ciw353. PMC 4981759. PMID 27418577.
- ↑ 2.0 2.1 2.2 2.3 American Thoracic Society. Infectious Diseases Society of America (2005). "Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia". Am J Respir Crit Care Med. 171 (4): 388–416. doi:10.1164/rccm.200405-644ST. PMID 15699079. http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/HAP.pdf
- ↑ Haessler S, Lagu T, Lindenauer PK, Skiest DJ, Priya A, Pekow PS; et al. (2017). "Treatment Trends and Outcomes in Healthcare-Associated Pneumonia". J Hosp Med. 12 (11): 886–891. doi:10.12788/jhm.2877. PMID 29091975.
- ↑ Chen JI, Slater LN, Kurdgelashvili G, Husain KO, Gentry CA (2013). "Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home". Ann Pharmacother. 47 (1): 9–19. doi:10.1345/aph.1R322. PMID 23324506.
- ↑ Webb BJ, Dangerfield BS, Pasha JS, Agrwal N, Vikram HR (2012). "Guideline-concordant antibiotic therapy and clinical outcomes in healthcare-associated pneumonia". Respir Med. 106 (11): 1606–12. doi:10.1016/j.rmed.2012.08.003. PMID 22917808.
- ↑ Grenier C, Pépin J, Nault V, Howson J, Fournier X, Poirier MS; et al. (2011). "Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia". J Antimicrob Chemother. 66 (7): 1617–24. doi:10.1093/jac/dkr176. PMID 21586592.
- ↑ Attridge RT, Frei CR, Pugh MJ, Lawson KA, Ryan L, Anzueto A; et al. (2016). "Health care-associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes". J Crit Care. 36: 265–271. doi:10.1016/j.jcrc.2016.08.004. PMC 5096991. PMID 27595461.
- ↑ Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF (2011). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 52 (3): e18–55. doi:10.1093/cid/ciq146. PMID 21208910. Retrieved 2012-09-11. Unknown parameter
- ↑ Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009). "Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 49 (3): 325–7. doi:10.1086/600877. PMID 19569969. Retrieved 2012-09-11. Unknown parameter
- ↑ Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J (2012). "Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 54 (5): 621–9. doi:10.1093/cid/cir895. PMID 22247123. Retrieved 2012-09-11. Unknown parameter